Application No. 10/647,023

## RECEIVED CENTRAL FAX CENTER

Customer No. 01933

JUL 1 8 2006

## REMARKS

On page 3 of the Response to Restriction Requirement filed on July 7, 2006, there was a minor clerical error in the compounds set forth in Example 5 and claim 60. The correct compound names are reproduced as follows, wherein the correction is in bold.

Applicants elect Example 5 (Claim 60).

Example 5

Disodium 4-cyano-2[[(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propoxy]carbonyl]benzyl phosphate (Disodium Salt of Example Number 5-16)

Claim 60. The triazole compound according to claim 1, wherein the compound is dihydrogen 4-cyano-2[[(1R,2R)-2-[[trans-2-[(1E,3E)-4-(4-cyano-2-fluorophenyl)-1,3-butadienyl]-1,3-dioxan-5-yl]thio]-1-(2,4-difluorophenyl)-1-[(1H-1,2,4-triazol-1-yl)methyl]propoxy]carbonyl]benzyl phosphate or a pharmacologically acceptable salt thereof.

Application No. 10/647,023

Customer No. 01933

If the Examiner has any comments, questions, objections or recommendations, the Examiner is invited to telephone the undersigned at the telephone number given below for prompt action.

Respectfully submitted,

Richard S. Barth Reg. No. 28,180

Frishauf, Holtz, Goodman & Chick, P.C. 220 Fifth Avenue, 16th Fl. (New York, NY 10001-7708 Tel. Nos. (212) 319-4900 Fax No.: (212) 319-5101

E-Mail Address: BARTH@FHGC-LAW.COM

RSB/ddf